Guggenheim starts Legence at Buy amid data center, life sciences tailwinds

As previously reported, Guggenheim analyst Joseph Osha initiated coverage of Legence (LGN) with a Buy rating and $41 price target The supplier of mechanical, electrical and plumbing solutions for commercial and industrial building applications is well positioned to benefit from growing demand from data center and life sciences end-markets, the analyst tells investors. The firm argues that premium multiple is “justified” by Legence’s revenue growth profile and competitive positioning.